Pfizer Inc (PFE): Shareholders' Equity
$86.78B
As of 2025-12-31
$85.49B
As of 2026-06-28
-3.3%
3-year compound annual growth
+6.5%
5-year compound annual growth
+2.9%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $86.78B | -1.9% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $88.50B | -0.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $89.29B | -6.9% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $95.92B | +23.8% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $77.46B | +22.0% | 2024-02-22, Balance as of period end |
| 2020-12-31 | $63.47B | 0.0% | 2023-02-23, Balance as of period end |
| 2019-12-31 | $63.45B | -0.5% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $63.76B | -11.0% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $71.66B | +19.7% | 2020-02-27, Balance as of period end |
| 2016-12-31 | $59.84B | -7.9% | 2019-02-28, Balance as of period end |
| 2015-12-31 | $65.00B | -9.2% | 2018-02-22, Balance as of period end |
| 2014-12-31 | $71.62B | -6.5% | 2017-02-23, Balance as of period end |
| 2013-12-31 | $76.62B | -6.2% | 2016-02-29, Balance as of period end |
| 2012-12-31 | $81.68B | -1.1% | 2015-02-27, Balance as of period end |
| 2011-12-31 | $82.62B | -6.4% | 2014-02-28, Balance as of period end |
| 2010-12-31 | $88.27B | -2.4% | 2013-02-28, Balance as of period end |
| 2009-12-31 | $90.45B | +56.6% | 2012-02-28, Balance as of period end |
| 2008-12-31 | $57.74B | -11.3% | 2011-02-28, Balance as of period end |
| 2007-12-31 | $65.12B | n/a | 2010-02-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| AbbVie Inc. (ABBV) | 2025-12-31 | -$3.27B | n/m |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $7.91B | +47.1% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $31.26B | +6.5% |
Compare PFE, ABBV, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗